KR102024836B1 - 동결건조된 리포좀 - Google Patents

동결건조된 리포좀 Download PDF

Info

Publication number
KR102024836B1
KR102024836B1 KR1020147012039A KR20147012039A KR102024836B1 KR 102024836 B1 KR102024836 B1 KR 102024836B1 KR 1020147012039 A KR1020147012039 A KR 1020147012039A KR 20147012039 A KR20147012039 A KR 20147012039A KR 102024836 B1 KR102024836 B1 KR 102024836B1
Authority
KR
South Korea
Prior art keywords
liposomes
composition
liposome
lyophilization
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147012039A
Other languages
English (en)
Korean (ko)
Other versions
KR20140092323A (ko
Inventor
도나 카브랄-릴리
로렌스 메이어
폴 타르디
데이비드 왓킨스
이 젱
Original Assignee
셀라토 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102024836(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀라토 파마슈티칼즈, 인코포레이티드 filed Critical 셀라토 파마슈티칼즈, 인코포레이티드
Publication of KR20140092323A publication Critical patent/KR20140092323A/ko
Application granted granted Critical
Publication of KR102024836B1 publication Critical patent/KR102024836B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
KR1020147012039A 2011-10-21 2012-10-15 동결건조된 리포좀 Active KR102024836B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197027220A Division KR102113753B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀

Publications (2)

Publication Number Publication Date
KR20140092323A KR20140092323A (ko) 2014-07-23
KR102024836B1 true KR102024836B1 (ko) 2019-09-24

Family

ID=48141268

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020147012039A Active KR102024836B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020197027220A Active KR102113753B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020227034406A Ceased KR20220141906A (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020217023773A Active KR102452305B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020207013990A Active KR102284689B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197027220A Active KR102113753B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020227034406A Ceased KR20220141906A (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020217023773A Active KR102452305B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀
KR1020207013990A Active KR102284689B1 (ko) 2011-10-21 2012-10-15 동결건조된 리포좀

Country Status (22)

Country Link
US (5) US10028912B2 (enExample)
EP (2) EP2768484B1 (enExample)
JP (6) JP6133308B2 (enExample)
KR (5) KR102024836B1 (enExample)
CN (2) CN104114156A (enExample)
AU (1) AU2012326370C9 (enExample)
BR (1) BR112014009305B1 (enExample)
CA (1) CA2852777C (enExample)
DK (1) DK2768484T3 (enExample)
ES (1) ES2750368T3 (enExample)
FR (1) FR19C1063I2 (enExample)
HR (1) HRP20191683T1 (enExample)
HU (2) HUE045978T2 (enExample)
IL (1) IL232161B (enExample)
LU (1) LUC00135I2 (enExample)
NL (1) NL301016I2 (enExample)
NO (1) NO2019041I1 (enExample)
PL (1) PL2768484T3 (enExample)
PT (1) PT2768484T (enExample)
RU (1) RU2648753C2 (enExample)
SI (1) SI2768484T1 (enExample)
WO (1) WO2013059133A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190111139A (ko) * 2011-10-21 2019-10-01 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CA2958769A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
CN113679689B (zh) 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法
IL292080B2 (en) 2015-11-11 2024-09-01 Celator Pharmaceuticals Inc Treatment regimens for hematologic cancers and methods of use thereof
SG10201913504XA (en) 2016-02-26 2020-03-30 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3069019A1 (en) * 2017-07-10 2019-01-17 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
WO2020068979A1 (en) 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
EP3990041B1 (en) * 2019-06-28 2025-08-06 Board of Regents, The University of Texas System Method of reconstituting liposomal annamycin
EP4003295A1 (en) * 2019-07-24 2022-06-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术（石家庄）有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060011044A1 (en) 2004-07-15 2006-01-19 Creative Technology Ltd. Method of composing music on a handheld device
US20110002982A1 (en) 2001-11-13 2011-01-06 Paul Tardi Lipid carrier compositions with enhanced blood stability

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JPS62501631A (ja) * 1985-01-11 1987-07-02 ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア リポソ−ムの保持法
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
IL125800A0 (en) * 1996-02-19 1999-04-11 Nycomed Imaging As Thermally stabilized contrast agent
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
NZ516648A (en) 1999-07-16 2004-01-30 Alza Corp A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
EP1448165B1 (en) 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipid carrier compositions and methods for improved drug retention
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US20060240090A1 (en) * 2003-04-02 2006-10-26 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
AU2005235455B2 (en) * 2004-04-22 2011-01-20 Jazz Pharmaceuticals Therapeutics, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20080107722A1 (en) 2004-11-18 2008-05-08 Paul Tardi Method For Loading Multiple Agents Into Delivery Vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
ES2909903T3 (es) 2007-02-16 2022-05-10 Rotalec Ip Holdings Llc Proporciones fijas de medicamentos para el tratamiento de cáncer hematopoyético y trastornos proliferativos
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
KR101563658B1 (ko) 2007-11-28 2015-10-27 셀라토 파마슈티칼즈, 인코포레이티드 개선된 탁산 전달 시스템
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
ES2547698T3 (es) 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Liposoma de irinotecán o su clorhidrato y método de preparación del mismo
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
HRP20191683T1 (hr) * 2011-10-21 2019-12-13 Jazz Pharmaceuticals Res Llc Liofilizirani liposomi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110002982A1 (en) 2001-11-13 2011-01-06 Paul Tardi Lipid carrier compositions with enhanced blood stability
US20060011044A1 (en) 2004-07-15 2006-01-19 Creative Technology Ltd. Method of composing music on a handheld device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190111139A (ko) * 2011-10-21 2019-10-01 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
KR102113753B1 (ko) * 2011-10-21 2020-05-21 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀

Also Published As

Publication number Publication date
RU2648753C2 (ru) 2018-03-28
DK2768484T3 (da) 2019-10-07
HUS1900047I1 (hu) 2019-11-28
JP6133308B2 (ja) 2017-05-24
FR19C1063I2 (fr) 2020-10-30
WO2013059133A1 (en) 2013-04-25
NO2019041I1 (no) 2019-11-25
JP2024045183A (ja) 2024-04-02
CN104114156A (zh) 2014-10-22
EP3572071A1 (en) 2019-11-27
KR20190111139A (ko) 2019-10-01
BR112014009305B1 (pt) 2023-01-24
AU2012326370A2 (en) 2014-06-12
LUC00135I2 (enExample) 2021-02-12
CA2852777C (en) 2020-10-27
EP2768484A4 (en) 2015-04-22
AU2012326370C9 (en) 2023-05-18
KR20210095746A (ko) 2021-08-02
JP2014532623A (ja) 2014-12-08
US20190070112A1 (en) 2019-03-07
KR20140092323A (ko) 2014-07-23
PT2768484T (pt) 2019-10-28
NL301016I2 (nl) 2020-04-16
AU2012326370B2 (en) 2017-06-01
RU2014120475A (ru) 2015-11-27
EP2768484A1 (en) 2014-08-27
JP6592556B2 (ja) 2019-10-16
SI2768484T1 (sl) 2019-12-31
CN108853031A (zh) 2018-11-23
RU2018107407A (ru) 2019-02-25
NL301016I1 (nl) 2019-10-30
US10835492B2 (en) 2020-11-17
EP2768484B1 (en) 2019-07-24
IL232161A0 (en) 2014-05-28
ES2750368T3 (es) 2020-03-25
JP2017160211A (ja) 2017-09-14
IL232161B (en) 2019-07-31
US10166184B2 (en) 2019-01-01
US20140255475A1 (en) 2014-09-11
HRP20191683T1 (hr) 2019-12-13
LUC00135I1 (enExample) 2019-10-25
HUE045978T2 (hu) 2020-01-28
BR112014009305A2 (pt) 2017-04-11
AU2012326370C1 (en) 2023-03-30
US20180161273A1 (en) 2018-06-14
JP2018150342A (ja) 2018-09-27
HK1201039A1 (en) 2015-08-21
PL2768484T3 (pl) 2019-12-31
JP6359717B2 (ja) 2018-07-18
JP7476161B2 (ja) 2024-04-30
KR102452305B1 (ko) 2022-10-07
KR20220141906A (ko) 2022-10-20
KR20200057104A (ko) 2020-05-25
US10028912B2 (en) 2018-07-24
JP2022033892A (ja) 2022-03-02
US20210169803A1 (en) 2021-06-10
RU2018107407A3 (enExample) 2021-05-04
AU2012326370A1 (en) 2014-06-05
KR102284689B1 (ko) 2021-08-02
KR102113753B1 (ko) 2020-05-21
US20230172855A1 (en) 2023-06-08
FR19C1063I1 (fr) 2019-11-22
JP2020007367A (ja) 2020-01-16
CA2852777A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
US20230172855A1 (en) Method of lyophilizing liposomes
EP3142656B1 (en) Multivesicular liposome formulations of tranexamic acid
PT1443900E (pt) Composições de veículo lipídico com estabilidade melhorada no sangue
RU2780489C2 (ru) Лиофилизированные липосомы
HK1201039B (en) Lyophilized liposomes
BR112020026629A2 (pt) Composições farmacêuticas na forma liofilizada

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000